Current Report Filing (8-k)
02 Maggio 2023 - 11:11PM
Edgar (US Regulatory)
0001446159
false
0001446159
2023-05-02
2023-05-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 2, 2023
Predictive Oncology
Inc.
(Exact name of Registrant as Specified in its
Charter)
| Delaware |
001-36790 |
33-1007393 |
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
2915 Commers Drive, Suite 900
Eagan, Minnesota |
55121 |
| (Address of Principal Executive Offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (651) 389-4800
Former Name or Former Address, if Changed Since
Last Report: Not Applicable
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common stock, $0.01 par value |
POAI |
NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
Director Resignation - David S. Smith
On May 2, 2023, David S. Smith,
JD, resigned as a director of Predictive Oncology Inc. (the “Company”), effective immediately. Mr. Smith’s resignation
is not due to a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Smith
will remain an advisor to the Board of Directors (the “Board”) and assume duties as an outside legal counsel to the Company.
Director Election - Dr. Veena Rao
Effective May 2, 2023, the
Board elected Dr. Veena Rao to the Board as a Class III director. Dr. Rao was appointed to fill the vacancy created by the resignation
of David S. Smith, JD. As a Class III director, Dr. Rao’s term will expire at the 2024 annual meeting of the Company’s stockholders.
Dr. Rao is an experienced
commercial and technical leader with over 25 years of experience in the areas of drug development, med tech, medical devices, and digital
health, having held a number of roles in both large and small company environments. She has a background in technology innovation, licensing,
and corporate business development in addition to having led launch and go-to-market teams for novel drug and medical device products.
Dr. Rao currently serves as Chief Business Officer of Portal Instruments, a needle-free drug delivery company, a position she has held
since December 2022. Previously, Dr. Rao served as Chief Commercial Officer at Beta Bionics from February 2021 until August 2022, and
as Head of Corporate Development & Strategy at Beta Bionics from October 2020 until February 2021. Prior to Beta Bionics, Dr. Rao
spent over a decade at Eli Lilly and Company with a number of commercial and technical roles including as Vice President of External Innovation
for the Lilly Device team. Dr. Rao has also served on the Board of Directors of Thermalin, Inc, and advisor to the PharmStars program,
and an advisor to Digbi Health. Dr. Rao has a B.S. in Chemical Engineering from the University of Minnesota, a PhD in Chemical Engineering
from Stanford University and an MBA from the University of Virginia Darden School of Business.
In connection with Dr. Rao’s
election to the Board and in recognition of the services that she will provide to the Company as a director, the Company will grant to
Dr. Rao shares of common stock from the Company’s Amended and Restated 2012 Stock Incentive Plan having a grant date value equal
to $5,000.
A press release announcing
the appointment of the new director is attached hereto as Exhibit 99.1.
| Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
|
|
| |
PREDICTIVE ONCOLOGY inc. |
| |
By: |
/s/ Bob Myers |
| |
|
Name: Bob Myers
Title: Chief Financial Officer |
Date: May 2, 2023
Grafico Azioni Predictive Oncology (NASDAQ:POAI)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Predictive Oncology (NASDAQ:POAI)
Storico
Da Feb 2024 a Feb 2025
